Adult Clinical Trials

None

27 trials identified.

An Open Label, Expanded Access Protocol Using (131)I-Metaiodobenzylguanidine (I-MIBG) Therapy in Patients with Refractory Neuroblastoma
Phase: Other
Sponsor: OTHER
Principal Investigator: Jessica Sun
Contact: Dr. Michael Armstrong
Phone: 919.684.3401
Reference Number: 00012332
View this trial at ClinicalTrials.gov

AHEP0731 Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NCS#683864) Added to High Risk Stratum Treatment
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00021079
View this trial at ClinicalTrials.gov

PBTC-029B: A Phase 1 and Phase II (B) and Re-Treatment (C) Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Daniel Landi
Contact: Pediatric Neuro Oncology
Phone: 919.684.0000
Reference Number: 00023836
View this trial at ClinicalTrials.gov

AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00025867
View this trial at ClinicalTrials.gov

AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00025879
View this trial at ClinicalTrials.gov

AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) including a Stratum Evaluating Dasatinib (IND#73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Trials Office
Phone: 919.684.3401
Reference Number: 00034203
View this trial at ClinicalTrials.gov

BMT CTM Protocol 1101 - A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
Phase: Phase III
Sponsor: Foundation (non-profit group) initiated
Principal Investigator: Joanne Kurtzberg
Contact: Dorothy Mazzitelli, RN
Phone: 919.668.1100
Reference Number: 00037305
View this trial at ClinicalTrials.gov

ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00039561
View this trial at ClinicalTrials.gov

ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Trials Office
Phone: 919.684.3401
Reference Number: 00041529
View this trial at ClinicalTrials.gov

Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of offthe-shelf ex vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Joanne Kurtzberg
Contact: Jennifer Baker, RN
Phone: 919.668.6536
Reference Number: 00041937
View this trial at ClinicalTrials.gov

A Compassionate Release Protocol: Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Allogeneic Transplantation using a Related Haplo-Identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-Malignant Disorders Requiring Allogeneic Transplantation
Phase: N/A
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Joanne Kurtzberg
Contact: Jennifer Baker, RN
Phone: 919.668.6536
Reference Number: 00045700

A CLINICAL AND MOLECULAR RISK-DIRECTED THERAPY FOR NEWLY DIAGNOSED MEDULLOBLASTOMA (SJMB12)
Phase: Phase II
Sponsor: Foundation (non-profit group) initiated
Principal Investigator: David Ashley
Contact: Jennifer King, RN
Phone: 919.668.5364
Reference Number: 00047285
View this trial at ClinicalTrials.gov

ANHL12P1 A Randomized Phase 2 study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00051843
View this trial at ClinicalTrials.gov

ACCL1033 A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00053228
View this trial at ClinicalTrials.gov

PBTC-042: Phase I Study of CDK 4-6 Inhibitor PD-0332991 (palbociclib; IBRANCE) in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Sponsor: Cooperative Group Initiated
Principal Investigator: David Vanmater
Contact: Pediatric Neuro Oncology
Phone: 919.684.0000
Reference Number: 00054303
View this trial at ClinicalTrials.gov

A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Timothy Driscoll
Contact: Jennifer Baker, RN
Phone: 919.668.1100
Reference Number: 00057365

AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00059538
View this trial at ClinicalTrials.gov

AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Trials Office
Phone: 919.684.3401
Reference Number: 00060489
View this trial at ClinicalTrials.gov

AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.6843401
Reference Number: 00060960
View this trial at ClinicalTrials.gov

A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults with Poor Risk CD30+ Hodgkin Lymphoma (HL) A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) and Limited Pediatric Blood and Marrow Transplant Consortium (PBMTC) Multicenter Clinical Trial
Phase: Phase I
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Paul Martin
Contact: Jennifer Baker, RN
Phone: 919.668.1100
Reference Number: 00062316
View this trial at ClinicalTrials.gov

AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3041
Reference Number: 00065203
View this trial at ClinicalTrials.gov

APEC14B1 Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Trials Office
Phone: 919.684.3401
Reference Number: 00068349
View this trial at ClinicalTrials.gov

AAML1331 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Susan Kreissman, MD
Phone: 919.684.3401
Reference Number: 00069267
View this trial at ClinicalTrials.gov

AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Trials Office
Phone: 919.684.3401
Reference Number: 00070111
View this trial at ClinicalTrials.gov

AOST1321 Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00070775
View this trial at ClinicalTrials.gov

Phase 1b study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children
Phase: Phase I
Sponsor: PI initiated
Principal Investigator: Eric Thompson
Contact: Pediatric Neuro Oncology
Phone: 919.684.0000
Reference Number: 00071228
View this trial at ClinicalTrials.gov

ACCL10P1 Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Research Team
Phone: 919.684.3401
Reference Number: 00081175
View this trial at ClinicalTrials.gov